Dupixent® (dupilumab) Recommended for EU Approval by th

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...

Related Keywords

Paris , France General , France , China , Massachusetts , United States , Georged Yancopoulos , Hannah Kwagh , Timothy Gilbert , Regeneron Velocimmune , Nathalie Pham , Sandrine Guendoul , Evan Berland , Felix Lauscher , Arnaud Delepine , Thomas Kudsk Larsen , Tarik Elgoutni , Corentine Driancourt , Vesna Tosic , Clinical Research Program , Us Department Of Justice , Linkedin , European Commission , Nasdaq , Exchange Commission , European Union , Dupilumab Development Program , European Commission Of Dupixent , Facebook , Regeneron Genetics Center , Instagram , Globenewswire Inc , Drug Administration , Regeneron Pharmaceuticals Inc , Euronext , European Medicines Agency , Medicinal Products , Human Use , Respiratory Questionnaire , Priority Review , Biologics License Application , Chief Scientific Officer , Nasal Polyposis , Prescribing Information , Regeneron Genetics , Forward Looking Statements , Medicines Agency , Product Candidates , Private Securities Litigation Reform Act , Statement Regarding Forward Looking ,